Company
Guerbet
Last checked: Nov 20, 2026Source: Drugs@FDA, ClinicalTrials.gov
NDAs and BLAs
5
3 still marketed
Novel approvals
5
Approvals since 2021
2
Originals and new uses
Phase 3 trials
10
Registered, any status
Trials by phase
All registered drug and biologic trials with this lead sponsor, any status. A public view of the pipeline.
- Phase 310
Recent approvals
Originals and efficacy supplements, newest first.
Drugs in development (0)
Investigational drugs, not yet FDA-approved, in this company's active or recent Phase 2 and 3 trials. Phase 3 first.
No investigational drugs in Phase 2 or 3 trials under this sponsor name.
Recruiting Phase 3 trials
Largest first.
- Evaluation of the Efficacy and Safety of Magnetic Resonance Angiography (MRA) Using Gadopiclenol Compared to Gadoterate Meglumine in the Assessment of Steno-occlusive Disease in Adult Patients With Suspected Vascular DiseasePivotal-lookingRecruiting
GuerbetIndustry
NCT07348640 · 315 participants (planned) · Start Jul 28, 2026 · Primary completion Dec 31, 2027
Drug: gadopiclenol; Gadoterate meglumine (Dotarem) · For: Steno-occlusive Disease
Sites: Birmingham, Alabama; Los Angeles, California; Aurora, Colorado · 43 sites in all
Marketed drugs (3)
Newest FDA action first.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.